组蛋白去乙酰化酶6在弥漫性大B细胞淋巴瘤中的表达及意义

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (2634 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the histone deacetylase 6 (HDAC6) expression in diffuse large B-cell lymphoma (DLBCL) and to analyze its relationship with the clinicopathological characteristics and survival. Methods: The clinical data from 93 DLBCL patients and 15 patients with reactive hyperplasia of lymph node who were treated in the Second Affiliated Hospital of Wenzhou Medical University from December 2007 to September 2015 was retrospectively analyzed. Cases were subjected to immunohistochemical staining for HDAC6 protein expression in the DLBCL tissue. SPSS was used to analyze the relationship between HDAC6 expression and various clinical factors, and the relationship between HDAC6 and survival. Results: High expression rates of HDAC6 protein in 93 DLBCL tissues were 69.9%, which was significantly higher than 20% in reactive hyperplasia of lymph node (P<0.05). In DLBLC, the ratio of IPI (0-2) in high expression group was significantly higher than that in low expression group but the ratio of increased LDH and β2-microglobulin in high expression group was significantly lower than that in low expression group (P<0.05). On Kaplan-Meier analysis, the 5-year overall survival and the 5-year progression free survival in high expression group was significantly higher than that in the low expression one. Conclusion: HDAC6 is highly expressed in DLBCL patients, patients with highly expressed HDAC6 represents low IPI score and light tumor burden. The highly expressed HDAC6 as a favorable prognostic factor has more prognostic value for DLBCL.

Key words： diffuse large B-cell lymphoma histone deacetylase 6 prognosis

Received: 01 July 2016

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIN Xiaoji
	QIAN Zijun
	NI Libin
	SUN Ni
	ZHOU Xiaohai
	TONG Huanhuan
	ZHOU Shuping
	YAO Rongxin.

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2017/V47/I6/421

[1] ARMITAGE J O, WEISENBURGER D D. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project[J]. J Clin Oncol, 1998, 16(8): 2780-2795.
[2] GASCOYNE R D. Emerging prognostic factors in diffuse large B cell lymphoma[J]. Curr Opin Oncol, 2004, 16(5):436-441.
[3] 赵静, 黄小芳, 杨开颜, 等. ZAP-70在B细胞非霍奇金淋巴瘤中的表达及其意义[J]. 温州医学院学报, 2009, 39(6): 616-618.
[4] MARQUARD L, GJERDRUM L M, CHRISTENSEN I J, et al. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutane-ous T-cell lymphoma[J]. Histopathology, 2008, 53(3): 267-277.
[5] SABATTINI E, BACCI F, SAGRAMOSO C, et a1. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview[J]. Pathologica, 2010, 102(3): 83-87.
[6] ROSENBERG S A. Validity of the Ann Arbor staging classification for the non-Hodgkin’s lymphomas[J]. Cancer Treat Rep, 1977, 61(6): 1023-1027.
[7] CHESON B D, HORNING S J, COIFFIER B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas[J]. J Clin Oncol, 1999, 17(4): 1244.
[8] ZHANG Z, YAMASHITA H, TOYAMA T, et al. HDAC6 expression is correlated with better survival in breast cancer[J]. Clin Cancer Res, 2004, 10(20): 6962-6968.
[9] LEE Y S, LIM K H, GUO X, et al. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis[J]. Cancer Res, 2008, 68(18): 7561-7569.
[10] AZUMA K, URANO T, HORIE-INOUE K, et al. Association of estrogen receptor alpha and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells [J]. Cancer Res, 2009, 69(7): 2935-2940.
[11] KAKIHANA M, OHIRA T, CHAN D, et al. Induction of Ecadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition[J]. J Thorac Oncol, 2009, 4(12): 1455-1465.
[12] HIDESHIMA T, BRADNER J E, WONG J, et al. Small molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma [J]. Proc Natl Acad Sci U S A, 2005, 102(24): 8567-8572.
[13] SAKUMA T, UZAWA K, ONDA T, et al. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma[J]. Int J Oncol, 2006, 29(1): 117-124.
[14] MARQUARD L, POULSEN C B, GJERDRUM L M, et al. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B-and T-cell lymphomas[J]. Histopathology, 2009, 54(6): 688-698.

[1]	. [J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2022, 52(8): 0-.